FXYD domain containing ion transport regulator 7Genealiases: []
Q-omics provides the consensus-scored FXYD7 profile across patient tissues and cancer cell-line models. FXYD7 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FXYD7 is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, FXYD7 RNA expression shows 12,071 significant gene co-expression associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, KICH, and STAD as cancer lineages where FXYD7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FXYD7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FXYD7 survival associations across molecular data types. FXYD7 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FXYD7 RNA expression–survival associations across cancer types. High FXYD7 expression shows unfavorable associations in KIRC, UCS, UCEC and UVM, but favorable associations in LUAD and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FXYD7 RNA expression.
This table summarizes FXYD7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FXYD7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FXYD7 shows lower tumor expression in KICH, UCEC, COAD, BRCA and PRAD and higher tumor expression in KIRC. The KICH box plot shows higher FXYD7 RNA expression in normal versus tumor tissue (log2 FC = −0.185, t-test p < 0.001).
This table shows molecular features associated with FXYD7 in patient tissues and cancer cell lines. In patient samples, FXYD7 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, FXYD7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
